Filing identity and reporting period
Important identification mismatch: The supplied filing is Unum Therapeutics Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 28, 2019. It is not a Cogent Biosciences filing. The company reported trading under ticker UMRX. The filing also presents unaudited fourth-quarter 2018 results, but the annual report is the primary reporting period summarized here.
Business context
Unum was a clinical-stage biotechnology company developing engineered T-cell cancer therapies. Its ACTR platform paired engineered T cells with tumor-targeting antibodies; its BOXR platform aimed to improve T-cell function in solid tumors. It had no approved products and no product-sales revenue.
- Four ACTR programs were in Phase I clinical trials: ACTR707 plus rituximab for relapsed/refractory non-Hodgkin lymphoma (NHL), ACTR087 plus rituximab for NHL, ACTR087 plus Seattle Genetics’ SEA-BCMA for multiple myeloma, and ACTR707 plus trastuzumab for HER2-positive solid tumors.
- BOXR1030, a GPC3-directed CAR T-cell candidate with an undisclosed “bolt-on” transgene, was in formal preclinical development.
- Management selected ACTR707 plus rituximab as the lead lymphoma program and completed enrollment in the ACTR087-plus-rituximab expansion cohort in the first quarter of 2019.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Collaboration revenue | $9.734 million | $8.360 million |
| Research and development expense | $38.285 million | $29.832 million |
| General and administrative expense | $7.454 million | $4.680 million |
| Total operating expenses | $45.739 million | $34.512 million |
| Operating loss | $36.005 million | $26.152 million |
| Net loss | $34.532 million | $25.492 million |
| Net loss per common share | $1.39 | $2.51 |
| Operating cash used | $32.489 million | $25.835 million |
Revenue came from the Seattle Genetics collaboration, including research and development funding; there was no product revenue. Gross margin and other product-margin measures are not meaningful for this pre-commercial company. FY 2018 expenses rose as clinical programs and manufacturing work expanded, and the net loss increased by about $9.0 million.
For the fourth quarter of 2018, revenue was $3.805 million, operating loss was $9.004 million, and net loss was $8.606 million. The filing provides no clear quarterly cash-flow figure.
- At December 31, 2018, cash and cash equivalents were $55.671 million and marketable securities were $22.923 million, or $78.594 million combined. Working capital was $56.1 million.
- Total assets were $85.927 million and total liabilities were $25.693 million. The company had no borrowings under its loan facility at year-end; up to $15 million was available, subject to the agreement’s terms.
- Cash, cash equivalents, and restricted cash increased by $27.326 million during 2018. Financing activities provided $70.346 million, principally from the IPO and concurrent private placement; operating activities used $32.489 million.
- The company raised approximately $63.9 million net from the IPO and $5.0 million in the concurrent private placement. Management estimated that cash, cash equivalents, and marketable securities would fund operating and capital needs into early 2021, but said those resources would not be sufficient to complete the planned Phase I trastuzumab trial and that additional funds would be needed.
Material changes, outlook, and risks
- Research and development expense increased 28% year over year, with higher spending on ACTR707 plus rituximab, SEA-BCMA, trastuzumab trial start-up, personnel, and manufacturing. Spending on ACTR087 plus rituximab decreased as planned enrollment fell.
- Unum adopted ASC 606 in 2018, changing collaboration-revenue recognition from a straight-line method to a cost-to-cost method. Adoption reduced opening accumulated equity by $6.188 million; FY 2018 collaboration revenue under the new method was $1.523 million lower than it would have been under the prior method. This limits direct comparability with 2017.
- Management expected to define a recommended Phase II dose for ACTR707 plus rituximab and begin expansion at that dose in the second half of 2019; it planned to report updated ACTR087-plus-rituximab data and additional SEA-BCMA and trastuzumab trial data later in 2019. These were expectations, not assured outcomes.
- Safety is a material development risk. In the ACTR087-plus-rituximab trial, the higher dose level exceeded the maximum tolerated dose: two patients experienced severe cytokine release syndrome, one patient had fatal neurotoxicity, and two patients later died of sepsis. The FDA clinical hold imposed in December 2017 was removed in February 2018 after the company provided requested information. ACTR707’s small early cohorts showed responses and no severe CRS or neurologic events reported at the data cutoff, but the sample was limited and results were preliminary.
- The independent auditor issued an unqualified opinion but included an emphasis-of-matter paragraph noting the company would require additional financing for future operations. Key risks include clinical efficacy and safety, funding needs, patient-specific manufacturing and supply capacity, regulatory approval, competition, and intellectual-property protection.
- In January 2019, the company amended its Pacific Western Bank facility to extend the borrowing availability period and interest-only period. The facility is secured by substantially all assets other than intellectual property and contains restrictive covenants.
Most important facts to verify
- Confirm the issuer: the supplied 10-K is for Unum Therapeutics, not Cogent Biosciences.
- Review subsequent clinical updates, especially ACTR707 response durability and safety, the selected dose, and the status of planned trial expansions.
- Assess actual cash burn, financing raised after year-end, and whether the stated early-2021 runway remains achievable; the filing explicitly identifies a funding shortfall for the trastuzumab trial.
- Check the effect of the ASC 606 accounting change when comparing reported collaboration revenue and losses across periods.
- Monitor the ACTR087 safety history, FDA actions, manufacturing reliability, and the terms and availability of the amended bank facility.